<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01636128</url>
  </required_header>
  <id_info>
    <org_study_id>UA-UB-101</org_study_id>
    <nct_id>NCT01636128</nct_id>
  </id_info>
  <brief_title>Urinary Biomarker Study With Sulindac and Difluoromethylornithine</brief_title>
  <official_title>A Phase 2 Urinary Biomarker Study of Polyamine Inhibition With Sulindac and Difluoromethylornithine (DFMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Prevention Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Prevention Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of 2 drugs (sulindac and
      Difluoromethylornithine (DFMO)) either alone or in combination on biomarkers found in urine.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding and staffing
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure intra-subject urine N1-monoacetylspermidine and dcSAM variability during the pre-drug phase</measure>
    <time_frame>Week 1-Week 2</time_frame>
    <description>Measure initial variability in levels of urinary biomarkers prior to initiation of drug treatment. Three blood draws over the first 14 days will be used to assess baseline variability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine dcSAM content of urine after 14 days of 500mg DFMO daily alone</measure>
    <time_frame>Week 4</time_frame>
    <description>Measure urinary biomarker dcSAM after 14 days of single agent DFMO. Measure urinary biomarker dcSAM after 14 days of single agent DFMO for treatment arm where DFMO alone is started week 2 (Treatment sequence A).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine N1-monoacetylspermidine content of urine after 14 days plus 1 day of 150 mg sulindac alone</measure>
    <time_frame>Week 4</time_frame>
    <description>Measure urinary biomarker dcSAM after 14 days of single agent sulindac. Measure urinary biomarker dcSAM after 14 days of single agent sulindac for treatment arm where sulindac alone is started week 2 (Treatment sequence B).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine dcSAM and N1-monoacetylspermidine content of urine after 14 days of 150 mg sulindac daily combined with DFMO at 500 mg/day</measure>
    <time_frame>Week 20</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine dcSAM content of urine after 14 days of 500mg DFMO daily alone</measure>
    <time_frame>Week 12</time_frame>
    <description>Measure urinary biomarker dcSAM after 14 days of single agent DFMO for treatment arm where DFMO alone is started week 10 (Treatment sequence B)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine N1-monoacetylspermidine content of urine after 14 days plus 1 day of 150 mg sulindac alone</measure>
    <time_frame>Week 12</time_frame>
    <description>Measure urinary biomarker dcSAM after 14 days of single agent sulindac. Measure urinary biomarker dcSAM after 14 days of single agent sulindac for treatment arm where sulindac alone is stated week 10 (Treatment sequence A).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine if 2 weeks is sufficient time for dcSAM levels and N1-monoacetylspermidine content of urine to recover after stopping DFMO and sulindac</measure>
    <time_frame>Week 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the length of time it takes for sulindac or DFMO to induce measurable changes in biomarker content of urine</measure>
    <time_frame>Week 3-Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the effect of dietary intake of polyamine measured using the Arizona Food Frequency Questionnaire</measure>
    <time_frame>Week 1-25</time_frame>
    <description>Quantitate dietary polyamine levels over the course of the study and evaluate the effects on biomarkers evaluated in the primary outcome measures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms</condition>
  <arm_group>
    <arm_group_label>Sulindac first (Treatment Sequence B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sulindac alone, washout, DFMO alone, then combination of sulindac and DFMO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DFMO first (Treatment Sequence A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFMO alone, followed by washout, sulindac alone, then combination of DFMO and sulindac</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>difluoromethylornithine</intervention_name>
    <description>500 mg oral for 14 days, combined with sulindac for 15 days</description>
    <arm_group_label>Sulindac first (Treatment Sequence B)</arm_group_label>
    <arm_group_label>DFMO first (Treatment Sequence A)</arm_group_label>
    <other_name>DFMO, eflornithine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulindac</intervention_name>
    <description>150 mg oral for 15 days, combined with DFMO for 14 days</description>
    <arm_group_label>Sulindac first (Treatment Sequence B)</arm_group_label>
    <arm_group_label>DFMO first (Treatment Sequence A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40-65 years

          -  Fluent in English

          -  PS 0 ECOG

          -  Must be able to discontinue the use of aspirin, aspirin containing products, and other
             non-steroidal anti-inflammatory agents for the duration of the study agent
             administration period

          -  Negative fecal occult blood test

          -  Hemoglobin &gt; 10g/dl, WBC must be &gt;4,000 mm3, platelets must be &gt; 100,000/mm3

          -  Serum creatinine must be &lt; 1.5 m/dl

          -  Serum bilirubin must be &lt; 2.0 mg/dl, AST and ALT must be &lt; 1.5x upper limit of normal
             range

          -  Female participants must be postmenopausal (at least 1 year since the last menstrual
             period), surgically sterilized, or willing to use an effective birth control method
             (e.g., hormonal contraceptive, oral contraceptives, intrauterine device, diaphragm
             with spermicide, or abstinence) for the duration of the study. Male subjects must use
             an effective method of birth control throughout the duration of the study and should
             not impregnate a female.

          -  Females of childbearing potential must have a negative serum pregnancy test prior to
             the start of study medication.

          -  Able to give signed, written informed consent

        Exclusion Criteria:

          -  Requires corticosteroids or nonsteroidal anti-inflammatory agents

          -  Individuals who are immunosuppressed by virtue of medication or disease. This includes
             participants known to have AIDS, subjects taking oral steroids, and subjects on
             immunosuppressants/immunomodulators (cyclosporine, chemotherapeutic agents, or
             biologic therapy)

          -  Current use of phenytoin or sulfonamides

          -  Current or recent (within 3 months) use of coumadin or other systemic anticoagulants.

          -  Frequently, chronic or moderate/severe gastric complaints. Upper gastrointestinal
             problems requiring prescription or nonprescription medical remedies for symptoms of
             heartburn, dyspepsia, nausea, or abdominal pain &gt; once per week on average

          -  History of peptic ulcer, occult or gross intestinal bleeding

          -  Known intercurrent illness, including but no limited to, inflammatory bowel disease,
             Crohn's disease, ulcerative colitis, symptomatic congestive heart failure, unstable
             angina pectoris, cardiac arrhythmia, renal disease, liver disease, ongoing or active
             infection, psychiatric illness, or other situations that would limit compliance or
             interfere with the ability to comply with the study regimen.

          -  History of bleeding or clotting disorders

          -  Individuals with seizures or history of seizures

          -  History of abnormal wound healing or repair, or conditions that predisposes to the
             same including diabetes

          -  Unwilling or unable to limit alcohol consumption to 2-3 servings per week during the
             study period (12oz beer, 1 oz per alcoholic beverage, 6 oz per wine)

          -  Individuals enrolled in or who plan to enroll in a clinical intervention trial. There
             must be a 30 day period between completing a previous study and enrolling in this
             study.

          -  Pregnant or lactating women

          -  Prior DFMO exposure

          -  History of allergic reaction (e.g., urticaria, asthma, rhinitis) or gastric
             intolerance attributed to NSAIDs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2012</study_first_submitted>
  <study_first_submitted_qc>July 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2012</study_first_posted>
  <last_update_submitted>July 28, 2014</last_update_submitted>
  <last_update_submitted_qc>July 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Patricia Thompson-Carino</investigator_full_name>
    <investigator_title>Associate Professor, Cellular and Molecular Medicine</investigator_title>
  </responsible_party>
  <keyword>Urinary</keyword>
  <keyword>biomarkers</keyword>
  <keyword>DFMO</keyword>
  <keyword>sulindac</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulindac</mesh_term>
    <mesh_term>Eflornithine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

